Clear All
793 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
HCPCS Generic Name Brand Name Strength SEER*Rx Category Major Drug Class Minor Drug Class Oral (Y/N) FDA Approval Year FDA Discontinuation Year CMS Effective Date CMS Discontinuation Date Status
Q5166 Denosumab-desu Jubereq, Osvyrti 1mg Immunotherapy Monoclonal Antibody RANKL No 2026 Jun 17, 2026 In Use
C9012 Arsenic Trioxide Trisenox unspecified Chemotherapy Miscellaneous Agent PML/RARa No 2000 Jan 1, 2001 Dec 31, 2001 No Longer Used
C9148 Teclistamab-cqyv Tecvayli 0.5mg Immunotherapy Monoclonal Antibody BCMA, CD3 No 2022 Mar 17, 2023 Jul 11, 2023 No Longer Used
Q5165 Denosumab-mobz Oziltus 1mg Ancillary Therapy Monoclonal Antibody RANKL No 2025 Jun 17, 2026 In Use
Q0167 Dronabinol Marinol 2.5 mg Ancillary Therapy Antiemetic CB1/CB2 Yes 1985 Apr 1, 1998 In Use
Q5162 Denosumab-nxxp Bildyos/Bilprevda 1mg Immunotherapy Monoclonal Antibody RANKL No 2026 Mar 18, 2026 In Use
J8502 Aprepitant Aponvie 1mg Ancillary Therapy Antiemetic Substance P/Neurokinin 1 No 2023 Mar 18, 2026 In Use
NA oxymetholone Anadrol-50 50 mg Ancillary Therapy Anabolic Steroid Androgen Yes 1972 In Use
NA Sotorasib Lumakras Multiple Chemotherapy RAS Inhibitor KRASG12C Yes 2021 In Use
J9340 Thiotepa Tepadina 15 mg Chemotherapy Alkylating Agent Nitrogen Mustard /Ethylenimine No 1959 Jan 1, 1984 Jul 9, 2025 No Longer Used
J9290 Mitomycin Mitosol 20 mg Chemotherapy Antitumor Antibiotic Alkylating Agent/ Mitomycin No 1981 Jan 1, 1994 Dec 31, 2010 No Longer Used
J2860 Siltuximab Sylvant 10 mg Immunotherapy Monoclonal Antibody IL-6 No 2014 Jan 1, 2016 In Use
J9053 Belantamab mafodotin-blmf Blenrep 0.1mg Immunotherapy Drug Antibody Conjugate BCMA No 2024 Jun 17, 2026 In Use
NA Erdafitinib Balversa 3mg, 4mg, 5mg Chemotherapy Tyrosine Kinase Inhibitor FGFR1, FGFR2, FGFR3, FGFR4 Yes 2019 In Use
Q5171 Denosumab (boncres) Boncresa 1mg Ancillary Therapy Monoclonal Antibody RANKL No 2025 Jun 17, 2026 In Use
NA Belumosudil Rezurock 200mg Chemotherapy Rho Kinase Inhibitor ROCK1, ROCK2 Yes 2021 In Use
Lazertinib Lazcluze 80mg, 240mg Chemotherapy Tyrosine Kinase Inhibitor EGFR Yes 2024 In Use
J9113 Cemiplimab-rwlc Libtayo 1mg Immunotherapy Checkpoint Inhibitor PD-1 No 2018 Oct 1, 2019 In Use
NA Ruxolitinib Jakafi 15 mg Chemotherapy Enzyme Inhibitor JAK 1/2 Yes 2011 In Use
NA Bicalutamide Casodex 50 mg Hormonal Therapy Androgen Receptor Inhibitor non-steriodal Yes 1995 In Use
J1626 Granisetron Hydrochloride Granisol [DSC], Sancuso, Sustol, Kytril 100 mcg Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist No 1993 Jan 1, 2009 In Use
J9225 Histrelin Acetate Vantas 50 mg Hormonal Therapy GnRH Agonist No 2004 Jan 1, 2008 In Use
NA Sunitinib malate Sutent 50 mg Chemotherapy Tyrosine Kinase Inhibitor VEGFR, FLT, PDGFR,KIT, RET, CSF Yes 2006 In Use
J1447 Tbo-filgrastim Granix 1 mcg Ancillary Therapy Immunostimulant Granulocyte Colony-Stimulating Factor No 2015 Jan 1, 2016 In Use
J9206 Irinotecan Camptosar 20 mg Chemotherapy Topoisomerase I Inhibitor Campothecin Analogs No 1996 Jan 1, 1998 In Use
The use of NA indicates that the HCPCS code was Not Available. NA may mean that a) the HCPCS code has not yet been created (new drug), b) the drug is given as an oral drug or alternative route (only in specific instances are HCPCS assigned to these medications), or c) the HCPCS could not be found or is truly not available.